title: Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.
abstract: Dendritic cells (DCs) play a role in natural killer (NK) cell activation, while NK cells are also able to activate and mature DCs. Toll-like receptors (TLRs) on the surface of DCs and NK cells induce the maturation and activation of these cells when engaged with their cognate ligand. We investigated to generate potent DCs by maturation with NK cells in the presence of TLR agonist in vitro and tested the efficacy of these DC vaccinations in mouse colon cancer model. The optimal ratios of DCs versus NK cells were 1:1 to 1:2. Immature DCs were mature with NK cells in the presence of lipopolysaccharide, which is TLR4 agonist, and further addition of IL-2 induced phenotypically and functionally mature bone marrow-derived DCs. These potent DCs exhibited not only high expression of several costimulatory molecules and high production of IL-12p40 and IL-12p70, but also high allogeneic T cells stimulatory capacity, and the induction of the high activities to generate tumor-specific CTLs. Consistently, vaccination with these DCs efficiently inhibited CT-26 tumor growth in mouse colon cancer model when compared to other vaccination strategies. Interestingly, combination therapy of these DC-based vaccines and with low-dose cyclophosphamide showed dramatic inhibition effects of tumor growth. These results suggest that the DCs maturated with NK cells in the presence of TLR agonist are potent inducer of antitumor immune responses in mouse model and may provide a new source of DC-based vaccines for the development of immunotherapy against colon cancer.
authors.affiliation: Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Jeonnam 519-809, Korea.
authors.forename: Thanh Nhan Nguyen
authors.initials: TN
authors.lastname: Pham
authors.forename: Cheol Yi
authors.initials: CY
authors.lastname: Hong
authors.forename: Jung-Joon
authors.initials: JJ
authors.lastname: Min
authors.forename: Joon-Haeng
authors.initials: JH
authors.lastname: Rhee
authors.forename: Truc Anh Thi
authors.initials: TA
authors.lastname: Nguyen
authors.forename: Byoung Chul
authors.initials: BC
authors.lastname: Park
authors.forename: Deok-Hwan
authors.initials: DH
authors.lastname: Yang
authors.forename: Young-Kyu
authors.initials: YK
authors.lastname: Park
authors.forename: Hyeong-Rok
authors.initials: HR
authors.lastname: Kim
authors.forename: Ik-Joo
authors.initials: IJ
authors.lastname: Chung
authors.forename: Hyeoung-Joon
authors.initials: HJ
authors.lastname: Kim
authors.forename: Je-Jung
authors.initials: JJ
authors.lastname: Lee
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000378:metabolism; D002277:Carcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology* / Q000637:transplantation; D005260:Female; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000502:physiology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D051197:Toll-Like Receptor 4 / Q000819:agonists; D051193:Toll-Like Receptors / Q000819:agonists*
chemical_list: D019496:Cancer Vaccines; D008070:Lipopolysaccharides; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors
references.citation: Cancer Immunol Immunother. 2004 Apr;53(4):275-306
references.pmid: 14648069
references.citation: Eur J Cancer. 2000 May;36(8):1060-6
references.pmid: 10885612
references.citation: Cell Immunol. 2006 Jun;241(2):102-12
references.pmid: 17049504
references.citation: J Exp Med. 2002 Feb 4;195(3):335-41
references.pmid: 11828008
references.citation: J Immunol. 1996 Feb 1;156(3):1138-42
references.pmid: 8557990
references.citation: Trends Immunol. 2004 Jan;25(1):47-52
references.pmid: 14698284
references.citation: Int Arch Allergy Immunol. 2006;140(1):53-72
references.pmid: 16534219
references.citation: J Immunol. 2003 Sep 1;171(5):2366-73
references.pmid: 12928383
references.citation: Immunol Lett. 2003 Jan 22;85(2):85-95
references.pmid: 12527213
references.citation: Cell Immunol. 2001 Oct 10;213(1):14-23
references.pmid: 11747352
references.citation: J Exp Med. 1982 Apr 1;155(4):1063-74
references.pmid: 6460831
references.citation: J Immunol. 2004 Jan 1;172(1):138-43
references.pmid: 14688319
references.citation: Mol Immunol. 2005 Feb;42(4):535-9
references.pmid: 15607810
references.citation: Cancer Invest. 2003;21(6):873-86
references.pmid: 14735692
references.citation: Nat Rev Immunol. 2002 Dec;2(12):957-64
references.pmid: 12461568
references.citation: J Exp Med. 2002 Feb 4;195(3):327-33
references.pmid: 11828007
references.citation: Nat Immunol. 2003 Feb;4(2):175-81
references.pmid: 12496964
references.citation: J Immunol Methods. 1999 Feb 1;223(1):77-92
references.pmid: 10037236
references.citation: J Clin Invest. 1998 Jan 15;101(2):429-41
references.pmid: 9435316
references.citation: Cancer Immunol Immunother. 2005 Jul;54(7):663-70
references.pmid: 15918076
references.citation: Cancer. 2007 Oct 1;110(7):1469-77
references.pmid: 17685394
references.citation: Clin Cancer Res. 2006 May 15;12(10):3092-8
references.pmid: 16707607
references.citation: Cancer Res. 2005 Oct 15;65(20):9525-35
references.pmid: 16230418
references.citation: Nat Rev Immunol. 2007 Jan;7(1):41-51
references.pmid: 17186030
references.citation: Cancer Immunol Immunother. 2007 Oct;56(10):1597-604
references.pmid: 17440723
references.citation: Exp Mol Med. 2009 Feb 28;41(2):61-6
references.pmid: 19287186
references.citation: J Immunol. 2005 Aug 1;175(3):1636-42
references.pmid: 16034103
references.citation: Blood. 2004 Sep 15;104(6):1778-83
references.pmid: 15166032
references.citation: J Surg Res. 2007 May 15;139(2):164-9
references.pmid: 17275030
references.citation: Cancer Immunol Immunother. 2002 Jan;50(11):588-96
references.pmid: 11807622
references.citation: Nat Rev Immunol. 2002 Dec;2(12):965-75
references.pmid: 12461569
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10116-21
references.pmid: 15218108
references.citation: J Exp Med. 2004 Aug 2;200(3):287-95
references.pmid: 15289500
references.citation: J Exp Med. 2002 Feb 4;195(3):343-51
references.pmid: 11828009
references.citation: Cancer Res. 1984 Nov;44(11):5439-43
references.pmid: 6488195
references.citation: Eur J Immunol. 2004 Feb;34(2):336-44
references.pmid: 14768038
references.citation: Blood. 2006 Mar 15;107(6):2432-9
references.pmid: 16291589
references.citation: J Immunol. 2004 May 1;172(9):5338-45
references.pmid: 15100273